
A patient taking clopidogrel experiences reduced antiplatelet activity after being prescribed another medication. Which of the following drugs is most likely responsible for this interaction by inhibiting the enzyme needed to activate clopidogrel?
A drug has a narrow therapeutic index, meaning that the difference between its effective dose and toxic dose is small. Which pharmacokinetic change is most likely to increase its toxicity risk even if the prescribed dose remains unchanged?





A
B
A
B
1) a
2) b
A
B
A
B
A
B